I was graduated from the ESBS (Ecole Supérieure de Biotechnologies de Strasbourg) in 2007. I also performed a PhD in immunology in Paris (Université Pierre et Marie Curie) working on the cutaneous immune system. I showed with my co-workers that skin vaccination could be more efficient than the classical intramuscular route. Indeed, the cutaneous route can trigger efficient immune responses notably against chronic diseases such as cancer or HIV (Human Immunodeficiency Virus).My work was published in several scientific journals and my thesis was translated into a scientific review on skin vaccination in an international journal.
When I ended my PhD, I worked for a small biotech company at the Pasteur Institute in Paris, which develops immunotherapies against cancer disease. With our co-workers and different private and academic partners (quality managers, CRO (clinical research organizations), patent specialists…) we performed the preclinical studies which allowed a universal cancer vaccine to access to the clinics (IMPD, Investigational Medicinal Product Dossier filing for the French Health Authorities). My experimental work was granted with the publication of 4 patents of which I am a co-inventor and by several scientific publications.
I then joined the parmaceutical industry where I first work as a national medical expert in transplantation (immunosuppressor molecules for transplant patients) . This experience allowed me to develop strong interactions with Key Opinion Leaders in the field of cardiac, renal and liver transplantation. It was also a way for me to get into the world of “clinical trials” and to familiarize with its regulatory environment. After this experience, I have taken part to the launch of a new biotherapy against immune related rheumatisms (anti-IL17). I was in charge of the phase III clinical trials follow-up (registration trials for filing of the drug in Europe), supervised national adboards of experts and organized national symposia with many experts in the field.
After this first experience in the parmaceutical industry, I worked as an « early assets » medical expert for France in a company developing immunotherapies against cancer. I was in charge of coordinating and implementing the early phase trials (Phase I and II) for France. I closely worked with the US head quarter and the preclinical research US teams. My major goal was to prove that France was attractive enough to perform such trials on its territory, an important role because it involves access to new therapies for patients with cancer. I have also interacted closely with the “market access” teams to implement methology strategies within clinical trials protocols to facilitate Market authorization for new cancer drugs in France and allow their reimbursement by the social insurance.
I have then decided to go back to the « academic world » and I currently work for a French research site labeled by the French National Cancer Institute (INCa). As a program manager, my job consists in driving strategically and operationally cancer multidisciplinary research programs. I closely work with oncologists, surgeons and basic researchers. An important part of my job consists in managing the cancer research community. I set up medical and scientific events with my co-workers, manage the international expert advisory board…I am also in charge of all academic and private research partnerships for the community and the regional network.
For many years I have been working with young children at school trying to educate them to the concept of the “immune system” and vaccination. I also teach at the ESBS as an external consultant in the field of clinical trials methodology and regulation as well as making them discover the pharmaceutical environment. In my current position I have also the opportunity to work with cancer patients trying to give them access to the concept of cancer research and its importance for the discovering of future treatments.